While sequencing technology is getting better and faster, it still isn't quite ready to be put to frequent use in the oncology ward, write the Wellcome Trust Center for Human Genetics' Danny Ulahannan and colleagues in a review in the British Journal of Cancer.

In the research setting, they note, there are still challenges in calling low-frequency variants that appear in cancer genomes as well as issues in identifying structural and copy-number variants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Electric DNA

Sequencing to Go

Following the Curve

Within the Bounds

This Week in PLOS

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.